TARGETING OF AML BY CD123-DIRECTED NK-CELL ENGAGER/NK CELL IMMUNE THERAPY AND HARNESSING APOPTOTIC MACHINERY BY BCL-2 INHIBITION

The Univeristy Of Texas M.D. Anderson Cancer Center

Investigators